Evidence map›Paper›PMID 42283399›Full record

Observational studyAddiction (Abingdon, England)2026

The association between naloxone distribution, buprenorphine treatment and retention and incident high-risk opioid prescribing with opioid overdose death in Kentucky, Massachusetts, New York and Ohio, United States: An exploratory community-level cohort study of data from the HEALing Communities Study.

Alexander Y Walley, Debbie M Cheng, Nathan Vandergrift, Marc Larochelle, JaNae Holloway, Jennifer L Brown, Redonna Chandler, Laura C Fanucchi, Daniel J Feaster, Patricia R Freeman and 10 more

Abstract readObservational Study
In one paragraph

Observational study in Addiction (Abingdon, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Alexander Y WalleyGrayken Center for Addiction and Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Boston Medical Center/Boston University School of Medicine, Boston, MA, USA.ORCID https://orcid.org/0000-0002-8158-4882
Debbie M ChengDepartment of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Nathan VandergriftRTI International, Durham, NC, USA.
Marc LarochelleGrayken Center for Addiction and Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Boston Medical Center/Boston University School of Medicine, Boston, MA, USA.
JaNae HollowayRTI International, Durham, NC, USA.
Jennifer L BrownDepartment of Psychological Sciences, Purdue University, West Lafayette, IN, USA.
Redonna ChandlerAddiction Policy Forum, Bethesda, MD, USA.
Laura C FanucchiDepartment of Medicine and Center on Drug and Alcohol Research, University of Kentucky College of Medicine, Lexington, KY, USA.
Daniel J FeasterBiostatistics and Bioinformatics Division, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Patricia R FreemanDepartment of Pharmacy Practice and Science and Center on Drug and Alcohol Research, University of Kentucky College of Medicine, Lexington, KY, USA.
Timothy HuntSocial Intervention Group, School of Social Work, Columbia University, New York, NY, USA.
Michelle R LofwallDepartment of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky College of Medicine, Lexington, KY, USA.
Hannah K KnudsenDepartment of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky College of Medicine, Lexington, KY, USA.
Edward V NunesDepartment of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA.ORCID https://orcid.org/0000-0002-2055-3425
Emmanuel OgaRTI International, Durham, NC, USA.
Douglas R OylerDepartment of Pharmacy Practice and Science and Center on Drug and Alcohol Research, University of Kentucky College of Medicine, Lexington, KY, USA.
Jeffrey H SametGrayken Center for Addiction and Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Boston Medical Center/Boston University School of Medicine, Boston, MA, USA.
Jennifer VillaniAddiction Policy Forum, Bethesda, MD, USA.ORCID https://orcid.org/0000-0003-2337-2504
Sharon L WalshDepartment of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky College of Medicine, Lexington, KY, USA.
T John WinhusenCenter for Addiction Research, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Funding

MassHEAL - Reducing overdose deaths by 40% (2019-2023)UM1DA049412 · NIDA · BOSTON MEDICAL CENTER · PI SAMET, JEFFREY H. · 2019 to 2023
$82.9M
Kentucky CAN HEAL (Communities and Networks Helping End Addiction Long-term)UM1DA049406 · NIDA · UNIVERSITY OF KENTUCKY · PI WALSH, SHARON L. · 2019 to 2022
$81.7M
CHASE: An Innovative County-Level Public Health Response to the Opioid Epidemic in New York StateUM1DA049415 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI EL-BASSEL, NABILA, GILBERT, LOUISA · 2019 to 2023
$77.3M
Optimizing HEALing in Ohio Communities (OHiO)-Health Equity SupplementUM1DA049417 · NIDA · OHIO STATE UNIVERSITY · PI FREISTHLER, BRIDGET J, WINHUSEN, T JOHN · 2019 to 2023
$66.3M
HEALing Communities Study Health Equity ResearchUM1DA049394 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI GLASGOW, LASHAWN, KNOTT, CHARLES · 2019 to 2023
$40.6M
NIDA NIH HHS UM1 DA049394NIDA NIH HHS UM1 DA049406NIDA NIH HHS UM1 DA049412NIDA NIH HHS UM1 DA049415NIDA NIH HHS UM1 DA049417NIH HHS UM1DA049394NIH HHS UM1DA049406NIH HHS UM1DA049412NIH HHS UM1DA049415NIH HHS UM1DA049417SAMHSA HHS
6 · The paper itself

Abstract

aimWe evaluated whether community-level naloxone distribution, medication for opioid use disorder treatment and retention and incident high-risk opioid prescribing rates were associated with opioid overdose death rates.

designObservational cohort conducted using 2019 to 2023 community-level data as an exploratory analysis of the HEALing (Helping to End Addiction Long-term®) Communities Study (HCS). Exposures included: (1) community-level naloxone distribution, past 12-months, categorized as ≤1000 units per 100 000 population vs. 1001-3000 units per 100 000 population vs. >3000 units per 100 000 population; (2) individuals treated with buprenorphine per 100 000 adult population in the current quarter; (3) individuals retained on buprenorphine for ≥ 180 days per 100 000 adult population in the current quarter; and (4) incident high-risk opioid prescribing per 100 000 adult population in the current quarter. SETTING AND

participantsPopulation-based study of 67 communities with 8.2 million adults in Kentucky, Massachusetts, New York and Ohio, USA, with required annual opioid overdose death rates of > 25 per 100 000 adult population and at least 30% rural. Across the 67 communities participating in the HCS, the adult population was 31% 18-34 years, 31% 35-54 years, 38% 55 years and over, 52% female, 73% non-Hispanic White, 15% non-Hispanic Black and 7.4% Hispanic. MEASUREMENTS: Quarterly community-level opioid overdose death rates from 2020 through 2023.

findingsThe 2019 annual rates were 40.4 opioid overdose deaths, 1287 naloxone rescue units distributed, 977.7 people received buprenorphine treatment, 546.3 people retained for more than 180 days on buprenorphine and 1266.7 high-risk opioid prescribing incidents per 100 000 population. In models adjusted for state, community age, sex, race/ethnicity, rurality, HCS intervention group assignment, 2019 rates of opioid overdose death, naloxone distribution, buprenorphine and high-risk opioid prescribing, and the ratio of opioid overdose deaths involving fentanyl, an increase in 100 people treated with buprenorphine per 100 000 population was associated with a decrease of 0.92 [95% confidence interval (CI) = -1.30 to -0.55] in the quarterly opioid overdose death rate, while an increase of 100 people retained on buprenorphine for more than 180 days per 100 000 population was associated with a decrease of 1.3 (95% CI = -1.8 to -0. 76). There were no statistically significant associations between naloxone distribution or incident high-risk opioid prescribing with change in quarterly opioid overdose death rates.

conclusionsIn this exploratory analysis, increases in both buprenorphine treatment and retention were statistically significantly associated with decreases in opioid overdose death rates, after adjusting for baseline rates of buprenorphine treatment and retention.

Indexed as

BuprenorphineDrug OverdoseNaloxoneNarcotic AntagonistsOpiate OverdoseOpioid-Related DisordersPractice Patterns, Physicians'AdultAnalgesics, OpioidCohort StudiesFemaleHumansMaleMassachusettsMiddle AgedNew YorkAnalgesics, OpioidBuprenorphineNaloxoneNarcotic Antagonistsbuprenorphinecommunity‐levelfentanylhigh‐risk opioid prescribingnaloxoneoverdose death

Identifiers

PMID42283399
PMCPMC13430559

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.